SAGE is to launch Foot & Ankle Specialist – European Edition from February 2011. The journal will be an international edition of Foot & Ankle Specialist  (FAS), a bimonthly controlled circulation journal launched in 2008 publishing peer-reviewed clinical information for foot and ankle caregivers. Written and edited by podiatrists and orthopaedic surgeons, FAS offers the latest techniques and advancements in foot and ankle treatment through research reports and reviews, case studies, and other evidence-based articles.

Read the full story here

BioMimetic Therapeutics Inc announced that the US Food & Drug Administration (FDA) has accepted for review its Premarket Approval (PMA) application for Augment Bone Graft for use in foot and ankle fusions in the US. The FDA has now filed the application and begun the comprehensive review of the clinical module, the company added.

Results from a late-stage trial of Amgen’s denosumab in advanced cancer patients with bone metastases showed that the drug delayed skeletal related events such as fracture, radiation to bone, surgery to bone or spinal cord compression. The phase 3 trial compared denosumab administered subcutaneously with FDA approved Zometa, or zoledronic acid, administered as an intravenous infusion to treat bone metastases in 1,776 advanced cancer patients with solid tumors.

The FDA has cleared Osteotech Inc.’s Plexur P biocomposite for use in spinal applications as a bone void filler and graft extender. Osteotech has already received FDA clearance for Plexur P for use in filling bony voids of the pelvis and extremities. The biocomposite has been used in tibial plateau fractures, tibial osteotomies and foot and ankle procedures. The company aims to immediately offer our Plexur P(TM) product to spine surgeons.